Towards Healthcare
Gene Therapy for Sickle Cell Disease Market Forecast 2025 to 2034

Gene Therapy for Sickle Cell Disease Market Emerging Demand

The global market is driven by a rise in SCD prevalence and R&D activities. North America dominated the market due to the increasing R&D investment from various companies.

Content

  • Insight Code: 6085
  • No. of Pages: 150+
  • Format: PDF/PPT/Excel
  • Published: September 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2022
  • Base Year: 2023
  • Estimated Years: 2024-2033

About The Author

Kesiya Chacko is an accomplished market research professional with over 4+ years of experience in the healthcare industry, known for delivering actionable insights and strategic analysis that empower healthcare organizations to navigate complex, rapidly evolving markets.

Kesiya began her research career with Precedence Research, where she built a strong foundation in pharmaceutical and healthcare market analysis. Today, she plays an integral role at Towards Healthcare, contributing to in-depth, client-centric research initiatives. She also brings her expertise to Statifacts, supporting broader research functions with a focus on cross-sector healthcare trends and data interpretation.

Her commitment to high-quality analysis, combined with a strong grasp of regulatory and market dynamics, makes her a trusted contributor to healthcare firms seeking future-ready, data-backed decisions. Kesiya’s work spans the analysis of industry trends, competitive benchmarking, and evaluation of regulatory and innovation-driven shifts.

Talk to us
FAQ's

The gene therapy for sickle cell disease market size, growth trends, and forecast for gene therapy in sickle cell disease from 2025 to 2034, driven by innovation and demand.

North America is currently leading the gene therapy for sickle cell disease market due to continuous investment in research and development of gene therapies by both large and small companies.

The gene therapy for sickle cell disease market includes 6 segments such as by therapy type, by vector type, by treatment approach, by technology, by end user, and by region.

Some key players include Bluebird Bio, Vertex Pharmaceuticals, CRISPR Therapeutics, Editas Medicine, and Sangamo Therapeutics.

Key trends include the increasing demand for in vivo therapy, growth in technological advancements, and innovations in gene editing technologies and delivery systems.

It utilizes a special enzyme (a fusion of Cas9 and reverse transcriptase) recommended by a prime editing guide RNA (pegRNA) to target a specific DNA location. 

US FDA, NIH, CDC, NHGRI, CMS, HHS, ClinicalTrials.gov, NHM, Medlineplus.gov
Any Questions